The Human Variable 

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.

Personalized CRISPR Remission™ for sarcoidosis introduces a state-dependent precision medicine framework integrating immune biology, environmental exposure, safety modeling, and CYNAERA predictive systems to improve durable response and reduce variability.

A new framework for disease prevalence estimation, the Diagnostic Multiplier™ (DM™) adjusts for underdiagnosis, diagnostic variability, and environmental exposure across conditions.

CRISPR Remission™ for Lyme disease introduces a personalized CRISPR framework integrating environmental burden, immune variability, and state-dependent intervention to address persistent Lyme and post-treatment Lyme disease.

State-dependent oral CRISPR delivery framework modeling uptake, EBV targeting, and gene editing efficiency. Explores how immune state, environmental burden, and physiology determine real-world therapeutic success.

CDF-Peds-LC™ was developed as CYNAERA’s proposed Composite Diagnostic Fingerprint for Pediatric Long COVID. It is a structured recognition and tracking framework designed to identify probable pediatric Long COVID through five interlocking domains: post-infection onset, multisystem symptom burden, post-exertional patterning, functional disruption, and fluctuation or relapse over time.